• Our work with Olink on plasma-based immuno-oncology (IO) applications has allowed the identification of tumor and immune changes associated with immune checkpoint inhibitor response/non-response.This is particularly exciting as we combine this technology with deep tumor-based analysis to understand tumor-immune interactions and establish predictive and/or monitoring tools for IO. The small volume required for Olink analysis is a game-changer as it allows multi-analyte assessment of samples and validation of findings by multiple orthogonal platforms.

    • Genevieve M. Boland

    • Director Melanoma Surgery Program, Massachusetts General Hospital, Boston

  • The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers

    • Tom Lanz

    • Principal Scientist, Pfizer Neuroscience

  • In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.

    • Assistant Professor Petter Brodin

    • Department of Medicine, Karolinska Institute, Stockholm

  • Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)

    • Professor Mike Snyder

    • Department of Genetics, Stanford University

  • My interest in biomarkers grew in parallel to the growth of Olink. Back in 2014, when I first selected the Olink technology for an important  EU-funded program that I was coordinating, the company had only a handful of employees. Since then, Olink’s growth was amazing. Yet, they still  behave like partners, not simple providers. I have since recommended Olink to many international colleagues.

    • Faiez Zannad

    • Professeur de Thérapeutique-Cardiologie Coordinateur, Centre d’Investigation Clinique Inserm, CHU, Université de Lorraine

  • We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.

    • Professor Leroy Hood

    • Institute for Systems Biology, Seattle

  • I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains

    • Professor Tomas Olsson

    • Center for Molecular Medicine, Karolinska Hospital, Stockholm

  • Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.

    • Professor C.Thomas Caskey

    • Baylor College of Medicine, Houston TX

  • We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.

    • Professor Mathias Uhlen

    • Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm
Read more about what our customers say about us

Olink news (June 3, 2020)

PEA on NGS, a game-changer for proteomics

In our efforts to enable the understanding of real-time human biology through accelerating proteomics, we are very proud to announce the groundbreaking developments that have enabled us to now launch Olink® Explore 1536. By combining our elegant PEA technology with state of the art NGS readout, we can now offer a higher multiplexing level using a semi-automated protocol, with increased throughput at a lower cost. Using only 3 μL of plasma or serum we can quantify close to 1500 proteins while maintaining the Olink hallmark of delivering high-quality data.

Publications

See all publications

News & Events Highlights

See all

The Olink Community at the Nobel Forum, Stockholm

View the video and get a flavor of the major international meeting, “Precision Proteomics to Drive Personalized Medicine“, which Olink  arranged at the Nobel Forum in Stockholm on June 19, 2018. This global event brought together leading scientists from both academia and industry to listen to a series of outstanding presentations and to engage in important discussions around the increasing importance of protein biomarkers for the development of more personalized healthcare.

Please join our community and get #Olinked by following us on LinkedIn